Home/Pipeline/LFD-200

LFD-200

Rheumatoid Arthritis

Phase 1Active

Key Facts

Indication

Rheumatoid Arthritis

Phase

Phase 1

Status

Active

Company

Lifordi Immunotherapeutics

About Lifordi Immunotherapeutics

Lifordi Immunotherapeutics is an early-stage biotech company translating the proven oncology success of antibody-drug conjugates (ADCs) into novel treatments for autoimmune and inflammatory diseases. The company's platform targets a highly internalized cell surface protein on myeloid and lymphoid cells to deliver therapeutic payloads directly to pathogenic immune cells. Backed by top-tier venture capital firms and led by an experienced management team, Lifordi is advancing its lead candidate, LFD-200, through Phase 1 trials in Rheumatoid Arthritis, aiming to establish a new paradigm in immunology therapeutics.

View full company profile

Therapeutic Areas

Autoimmune Disorders Inflammatory Disorders

Other Rheumatoid Arthritis Drugs

Drug	Company	Phase	Status
Early Detection Test for Rheumatoid Arthritis	Age Labs	Development	Active
Piclidenoson (CF101)	Can Fite Biopharma	Phase II/III	Previously Active
ERNA-201	Eterna Therapeutics	Preclinical	Active Discovery/Research
Tc99m Tilmanocept	Navidea Biopharmaceuticals	Phase 2/3	Jeopardized (Bankruptcy)
Monoclonal Antibody Biosimilar (Anti‑TNF)	USV Biologics Division	Phase 1	Active
Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure)	LFB	Pre-clinical	Development (Partnership)
EYD-001 (Takinib analog)	EydisBio	Preclinical	In vivo efficacy and pilot safety in progress
MEV-N01	Mesenbio	Pre-clinical	Active
CIT-013	Citryll	Phase 2a	Active
Restem-L	Restem	Phase 2	Active
ASIT Platform	Ahead Therapeutics	Pre-clinical	Active
AX-158	Artax Biopharma	Phase 2	Active